Your browser doesn't support javascript.
loading
RAD52: Paradigm of Synthetic Lethality and New Developments.
Rossi, Matthew J; DiDomenico, Sarah F; Patel, Mikir; Mazin, Alexander V.
Afiliación
  • Rossi MJ; Department of Biochemistry and Structural Biology, University of Texas Health Science Center, San Antonio, TX, United States.
  • DiDomenico SF; Department of Biochemistry and Structural Biology, University of Texas Health Science Center, San Antonio, TX, United States.
  • Patel M; Department of Biochemistry and Structural Biology, University of Texas Health Science Center, San Antonio, TX, United States.
  • Mazin AV; Department of Biochemistry and Structural Biology, University of Texas Health Science Center, San Antonio, TX, United States.
Front Genet ; 12: 780293, 2021.
Article en En | MEDLINE | ID: mdl-34887904
ABSTRACT
DNA double-strand breaks and inter-strand cross-links are the most harmful types of DNA damage that cause genomic instability that lead to cancer development. The highest fidelity pathway for repairing damaged double-stranded DNA is termed Homologous recombination (HR). Rad52 is one of the key HR proteins in eukaryotes. Although it is critical for most DNA repair and recombination events in yeast, knockouts of mammalian RAD52 lack any discernable phenotypes. As a consequence, mammalian RAD52 has been long overlooked. That is changing now, as recent work has shown RAD52 to be critical for backup DNA repair pathways in HR-deficient cancer cells. Novel findings have shed light on RAD52's biochemical activities. RAD52 promotes DNA pairing (D-loop formation), single-strand DNA and DNARNA annealing, and inverse strand exchange. These activities contribute to its multiple roles in DNA damage repair including HR, single-strand annealing, break-induced replication, and RNA-mediated repair of DNA. The contributions of RAD52 that are essential to the viability of HR-deficient cancer cells are currently under investigation. These new findings make RAD52 an attractive target for the development of anti-cancer therapies against BRCA-deficient cancers.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Genet Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: CH / SUIZA / SUÍÇA / SWITZERLAND

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Genet Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: CH / SUIZA / SUÍÇA / SWITZERLAND